Cigna Group Files 8-K Report

Ticker: CI · Form: 8-K · Filed: 2024-03-07T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: CI

TL;DR

Cigna Group filed an 8-K, likely routine financial updates.

AI Summary

On March 7, 2024, The Cigna Group filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided text snippet.

Why It Matters

This filing indicates routine corporate reporting by The Cigna Group to the SEC, which may contain updates on financial statements or disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing appears to be a standard 8-K for disclosures and exhibits, not indicating any immediate or significant risks.

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The provided text snippet indicates that 'Financial Statements and Exhibits' are part of the filing, but does not list the specific documents.

What is the purpose of the Regulation FD Disclosure mentioned in the filing?

Regulation FD (Fair Disclosure) ensures that material information is disclosed to all investors simultaneously, preventing selective disclosure.

When was The Cigna Group incorporated?

The filing states the state of incorporation is Delaware, but the specific date of incorporation is not provided in this snippet.

What is the primary business of The Cigna Group?

The Standard Industrial Classification code [6324] indicates the company operates in 'HOSPITAL & MEDICAL SERVICE PLANS'.

Has The Cigna Group undergone any name changes recently?

The filing mentions former company names 'Cigna Corp' (name change date 20181221) and 'Halfmoon Parent, Inc.' (name change date 20180508), indicating past restructuring or rebranding.

From the Filing

0000950159-24-000103.txt : 20240307 0000950159-24-000103.hdr.sgml : 20240307 20240307065512 ACCESSION NUMBER: 0000950159-24-000103 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240307 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 24728107 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K false 0001739940 0001739940 2024-03-07 2024-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K     CURRENT REPORT   Pursuant to Section 13 or 15(d) of the   Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) March 7, 2024   The Cigna Group   (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of   incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.)   900 Cottage Grove Road Bloomfield , Connecticut 06002   (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code:   ( 860 ) 226-6000   Not Applicable   (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐            Item 7.01 Regulation FD Disclosure. Outlook and Investor Day Information On March 7, 2024, The Cigna Group (the “Company”) issued a press release noting that the Company will host its Investor Day, both in person in New York, New York and virtually, beginning at approximately 8:30 a.m. eastern time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. During Investor Day, as well as in meetings with investors and ana

View on Read The Filing